Blood cancers

CAR T-cell therapy access expands to DLBCL patients as local manufacture starts

Access to subsidised CAR T-cell therapy tisagenlecleucel (Kymriah) will be expanded to include adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL), transformed follicular lymphoma and primary mediastinal B cell lymphoma. Previously, subsidised therapy was only provided to children and young adults with acute lymphoblastic leukaemia (ALL). The announcement from the Federal ...

Already a member?

Login to keep reading.

© 2021 the limbic